Alnylam Pharmaceuticals, Inc. ALNYincurred a loss of $1.22 per share (excluding stock based compensation expense), wider than the year ago loss of $1.06 per share and wider than the Zacks Consensus Estimate of a loss of $1.18
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться